Section 45 Expenditure on scientific research.

Income-tax Act, 2025

At a Glance

Clause 45 of the Income Tax Bill, 2025 (Old Version) provides deductions for capital or revenue expenditure on scientific research related to a taxpayer's business, including special deeming rules for expenditure incurred within three years prior to commencement, and specified in-house R&D deductions for eligible companies (notably in bio-technology and certain manufacturers). It affects businesses undertaking scientific research, companies with in-house R&D, and payors to approved research entities. Effective dates or decision dates: Not stated in the document.

Background & Scope

Statutory hook: Clause 45, Income Tax Bill, 2025 (Old Version) - dealing with "Expenditure on scientific research" under profits and gains of business or profession. The clause aims to prescribe deductible expenditure for scientific research across capital and revenue heads, set deeming provisions for pre-commencement expenditure, permit deductions for in-house R&D for specified companies, and allow deductions for sums paid to approved research associations, universities, national laboratories, IITs and specified persons subject to conditions and prescribed approvals. Definitions provided in the clause include "National Laboratory", "specified person" and a deeming of "land" to include interests in land; the Bill also refers to "Schedule XIII" (not reproduced here) to determine excluded articles/things. The text refers repeatedly to a "prescribed authority" and to conditions "as prescribed".

Statutory Provision Mode

Text & Scope

Clause 45 allows a deduction for expenditure incurred on scientific research related to the business of the assessee. It covers:

• Capital expenditure (excluding acquisition of land as such or as part of any property) and revenue expenditure, with both categories expressly listed.
• Expenditure incurred within three years immediately preceding commencement of business on: (i) salary to employees engaged in such scientific research; and (ii) purchase of materials used in such research - but only to the extent certified by the prescribed authority; such expenditure is deemed to have been incurred in the tax year in which business is commenced.
• A deeming for capital expenditure incurred within three years immediately preceding commencement: aggregated and deemed incurred in the tax year of commencement.
• For companies in bio-technology or manufacturers of items not specified in Schedule XIII, deduction for expenditure (other than land/building costs) on approved in-house R&D facilities subject to prescribed conditions; such deductions cannot be claimed under other provisions and are conditional on approval and compliance with prescribed documentation.
• Deductions for sums paid to specified research associations, universities, national laboratories, IITs and approved companies provided the sums are directed to be used for programmes approved by the prescribed authority and subject to prescribed approvals and documentation.
• Non-duplication rules: expenditure allowed under certain clauses cannot be claimed under other provisions; where an asset represents such expenditure and deduction is taken, section 33(3) deductions are barred for that asset.
• Administrative provisions: Board referrals to Central Government or prescribed authority for questions on whether activities/assets constitute scientific research; finality of those decisions; rules for amalgamation transfers; and definitions for certain terms.

Interpretation

The clause intends to incentivise business-related scientific research by allowing current deductions for revenue expenditure and capital expenditure (subject to exclusions like land cost) and by providing mechanisms to treat pre-commencement expenditure as incurred in the year of commencement. The presence of approval and certification requirements (prescribed authority; prescribed conditions and forms) signals a controlled administrative regime - deductions are conditional on external certification/approval rather than being purely self-assessed. The clause also seeks to avoid double benefits by excluding concurrent claims under other provisions.

Exceptions/Provisos

Key carve-outs and conditions include:

• No deduction for acquisition cost of land (as such or as part of property).
• Pre-commencement revenue expenditures qualify only if certified by the prescribed authority and within a three-year window; capital pre-commencement expenditure is deemed to the year of commencement only if within three years.
• Company in-house R&D deduction excludes cost of land/building and is available only where the R&D facility is approved; further, companies approved under the subsection (3)(b)(ii) are ineligible for the same subsection (2)(c)(ii) - i.e., a particular approval status may preclude this deduction.
• Sums paid to research entities are deductible only where expressly directed to approved research programmes and the recipient/entity is approved and specified; compliance documentation and notification by Central Government are required.
• Section 33(3) deductions barred for assets whose cost forms the basis of deductions under this clause.

Illustrations

• Example 1: A startup incurs expenditure on prototypes and pays salaries to R&D staff 18 months before formal commencement. If the prescribed authority certifies those salary/material costs as research-related, the expenditure is deemed incurred in the year of commencement and a deduction is allowable. (Details of certification procedure: Not stated in the document.)

• Example 2: A biotechnology company constructs an in-house R&D facility (excluding land cost) and obtains prescribed authority approval for the facility; it may claim deduction for qualifying in-house R&D expenditure subject to prescribed conditions. (Exact manner and limits: Not stated in the document.)

Interplay

The clause expressly prevents duplication by barring deductions under other provisions for expenditure allowed under specified sub-clauses and by excluding section 33(3) for assets already represented in deductions here. It references Schedule XIII (to identify excluded manufactured articles) and cross-refers to other statutory sections (section 33(3)). The clause repeatedly invokes "prescribed authority" and "as prescribed" - indicating intended subordinate legislation (rules, notifications) will govern procedure, approvals and certification. Specific rules/regulations/circulars are Not stated in the document.

Differences Between Section 45 of the Income-tax Act, 2025 and Clause 45 of the Income Tax Bill, 2025 (Old Version) 

• Structure and numbering: The Act (Document 1) structures sub-sections differently from the Bill (Document 2). What is contained in sub-section (1)(a)/(b)/(c) in the Act is arranged as sub-section (1) and (2)(a)/(b) in the Bill.
  • Practical impact: purely editorial/formatting; no substantive tax consequence.
• Expression re: capital and revenue categories: The Bill explicitly lists "(a) capital expenditure...; or (b) revenue expenditure; or (c) both" in sub-section (1). The Act states in sub-section (1)(a) a deduction for "expenditure, being in the nature of-- (i) capital expenditure... or (ii) revenue expenditure" (without the explicit "(c) both").
  • Practical impact: semantic; both texts allow capital and revenue deductions-no clear substantive divergence.
• Pre-commencement expenditure rule placement and wording: The Bill places the deeming/provisions for pre-commencement salary/materials and capital expenditure in sub-section (2)(a) and (2)(b). The Act consolidates similar rules in sub-section (1)(b) and (1)(c). Wording differs: the Bill's sub-section (2)(a) ends sentence punctuation differently ("...expenditure shall be deemed...") whereas the Act states "such expenditure shall be deemed..."
  • Practical impact: no material change to substantive operation; slight drafting differences that may affect textual parsing but not legal effect.
• Company in-house R&D concession: Both texts allow deduction for specified companies (biotechnology or manufacturers not listed in Schedule XIII) for in-house R&D subject to approval. The Bill places this at sub-section (2)(c)(i)-(iv) and (2)(c)(i) includes "not being expenditure in the nature of cost of any land or building". The Act places the same concept at sub-section (2)(i)-(v) with similar exclusion and adds explicit clause (v) expanding definition for drugs and pharmaceuticals.
  • Practical impact: substantively similar; the Act's numbering and explicit (v) mirrors the Bill's clause (d) but in different location-no substantive divergence identifiable from the texts provided.
• Definitions / modifications to 'salary' and other terms: The Act contains an extended sub-section (11) with detailed modifications to the meaning of "salary", provisions about "National Laboratory" and "specified person," and a definition of "land" for sub-section (1)(a)(i). The Bill's clause 11 (In this section) is shorter: it defines "National Laboratory", "specified person", and states "land includes any interest in land" but does not contain the explicit modifications to sections 16 and 18 regarding "salary".
  • Practical impact: the Act introduces precise cross-references and modifications to sections 16 and 18 (as to salary), which could materially affect the ambit of deductible salary payments for pre-commencement and research employees; this is a substantive addition present in the Act but absent from the Bill as reproduced.
• Prescribed authority references and finality: Both texts permit Board referrals and final decisions by Central Government or prescribed authority. The Act's sub-section (9) distinguishes referral for sub-section (3)(a) to Central Government and other activities to prescribed authority; the Bill's sub-section (9) uses similar wording but slightly shorter.
  • Practical impact: no clear substantive divergence.
• Minor editorial differences: Differences in punctuation, ordering of clauses (for example, Act has explicit clause (6)-(10) in slightly different order), and phraseology (e.g., "as may be prescribed" vs "as prescribed") appear throughout.
  • Practical impact: likely none substantive but may affect interpretation in close cases-drafters or courts may read the Act more precisely due to explicit cross-references.

Practical Implications

• Compliance & risk: Claimants must secure certification/approval from the prescribed authority for pre-commencement revenue costs and for in-house R&D facilities; failure to obtain or retain approvals risks denial of deductions. The text emphasises external validation over self-assessment.
• Record-keeping: Taxpayers should maintain detailed contemporaneous records of research activities, salary allocations, materials consumed, asset costing and approvals to support certification; specific forms/timelines are Not stated in the document.
• Tax planning constraints: The non-duplication rules and bar on section 33(3) deductions for the same assets limit opportunities to obtain multiple benefits for the same expenditure.
• M&A/amalgamation: Transferee companies receiving assets representing research capital expenditure will take the same position as the transferor for deduction purposes; ensure due diligence on approvals and historical deductions.

Key Takeaways

• Clause 45 permits deductions for capital and revenue expenditure on business-related scientific research, subject to exclusions and approvals.
• Pre-commencement expenditure within three years may be deemed to the year of commencement if certified by the prescribed authority.
• Special regime for eligible companies' in-house R&D (biotech and certain manufacturers), conditional on prescribed authority approval and documentation.
• Deductions require prescribed certification/approvals and are administratively controlled; non-duplication rules prevent multiple claims for the same cost.
• Definitions and cross-references indicate further rule-making and subordinate instruments will be central to practical implementation; those instruments are Not stated in the document.

Full Text:

Section 45 Expenditure on scientific research.